The global generalized myasthenia gravis (GMG) management market is experiencing robust growth, as highlighted in a recent report by Future Market Insights. Valued at USD 1.32 billion in 2023, the market is expected to expand at an impressive compound annual growth rate (CAGR) of 7.6% over the next decade, reaching an estimated USD 2.96 billion by 2033.
Generalized myasthenia gravis, a rare autoimmune disorder, causes debilitating muscle weakness and fatigue due to antibodies disrupting the communication between nerves and muscles. This condition primarily affects quality of life, particularly as its prevalence rises with an aging global population.
Recent statistics from the National Library of Medicine reveal that in the United States alone, the incidence rate of GMG stands at 20 per 100,000 people. Key demographic trends include a higher prevalence among females under 40 and males over 50, while childhood cases are more commonly observed in Asian populations. Notably, 50% of pediatric cases occur in individuals under the age of 15. Improved healthcare data collection and a global rise in disease prevalence have further underscored the growing need for effective GMG management solutions.
Advocacy and awareness efforts are gaining momentum, with organizations like the Myasthenia Gravis Foundation of America (MGFA) at the forefront. The MGFA’s initiatives, such as designating June as Myasthenia Gravis Awareness Month, are making strides in educating the public about GMG. Their comprehensive outreach campaigns, which include the distribution of a 23-page educational toolkit, aim to empower patients and healthcare professionals alike. These efforts have contributed to a notable increase in the patient population seeking diagnosis and treatment.
As advancements in medical research and innovative therapies continue to emerge, stakeholders across the healthcare sector are stepping up to address the unmet needs of GMG patients. The global GMG management marketβs evolution highlights the importance of cross-sector collaboration, advocacy, and investment in research to enhance the quality of life for individuals living with this rare autoimmune disorder.
Key Takeaways:
- On the global level, the diseaseβs incidence has risen substantially over recent years. This surge is attributed to increased disease awareness and diagnosis rates in both developed and developing nations. The nation’s massively improved reimbursement guidelines concerning the disorder are cruising sales growth.
- On the basis of the study conducted by the National Organization for Rare Disorders (NORD), the condition’s prevalence in the United Kingdom is estimated to be 15 per 100,000 people, a figure that has risen over time. The popularity of novel therapeutic approaches is growing in tandem with the escalating diagnosis speed and favorable reimbursement guidelines for the ailment.
- This is expected to surge the attempts of the industryβs prominent stakeholders in order to establish and obtain approval for novel drugs to treat the illness. The age structure of the population is expected to be another vital factor driving market growth.
- The proportion of people aged 80 and up in the EU population is predicted to more than double between 2021 and 2100, soaring from 6.0% to 14.6%. On the basis of the MDPI Journal of Clinical Medicine, the prevalence of the ailment surges progressively with age. The 60-89-year-old age group has the greatest incidence. As a result, the disease’s prevalence is increasing as the population’s average lifespan rises.
- On the basis of the 2020 epidemiology of myasthenia gravis article posted by Value in Health Journal, the older population comprises of higher incidence of the ailment than younger ages. Furthermore, in the United Kingdom, the pervasiveness of the disorder in the aging population was 46.4 per 100,000, in comparison to 12 per 100,000 in young adulthood.
Soaring Demand for Market Information: Uncover Detailed Trends and Insights in Our Report!
Competitive Landscape:
Key players in the global generalized myasthenia gravis (GMG) management market are strengthening the portfolio, pipeline, and treatment emphasis on unique disease treatments.
More Insights into the Generalized Myasthenia Gravis (GMG) Management Market:
The North American market is anticipated to dominate the global GMG management market. In 2020, the North American market was valued at worth USD 0.58 billion. The soaring incidence of the illness and the region’s aging population are the contributing factors to market growth during the forecast period. Furthermore, the region’s established healthcare facilities and favorable reimbursement policies are striving to improve diagnosis and therapy rates in both emerging and advanced economies.
Key Companies Profiled:
- Alexion Pharmaceuticals,
- Argenx,
- UCB Biopharma,
- Horizon Therapeutics,
- Halozyme Therapeutics,
- Hoffmann-La Roche AG,
- Janssen Research & Development, LLC,
- Immunovant Sciences GmbH,
- Sanofi,
- Cartesian Therapeutics
Key Segments Profiled in the Generalized Myasthenia Gravis (GMG) Management Industry Survey:
By Drug Types:
- Monoclonal Antibodies
- FcRn Inhibitors
- Corticosteroid
- Cholinesterase Inhibitors
- Pharmacotherapy
- Therapeutic Plasma Exchange
By End Users:
- Hospitals
- Specialty Clinics
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
ππ±π©π₯π¨π«π π ππβπ¬ πππ₯ππππ ππ§π π¨π’π§π ππ¨π―ππ«ππ π π¨π§ ππππ₯ππ‘πππ«π πππ«π€ππ ππ§π¬π’π π‘ππ¬ ππ¨π¦ππ’π§:
Surface Disinfectants Industry
Aspergillosis Treatment Industry
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:Β Β Β Β Β Β Β Β
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries:Β sales@futuremarketinsights.com
Website:Β https://www.futuremarketinsights.com
LinkedIn|Β Twitter|Β Blogs | YouTube